Animal-derived vaccines are vaccines developed using components obtained from animals, such as viruses or bacteria. These vaccines have been instrumental in preventing various infectious diseases in both animals and humans. Common examples include vaccines for influenza, rabies, and certain types of hepatitis. In animal-derived vaccines, the pathogen is either attenuated (weakened) or inactivated to stimulate an immune response without causing disease. These vaccines often use animal cells or tissues as a culture medium for the growth of the pathogen during the manufacturing process. Animal-derived vaccines have contributed significantly to veterinary medicine, protecting livestock and domestic animals from contagious diseases. Moreover, some human vaccines, particularly those against influenza, have historically utilized embryonated chicken eggs as a medium for virus propagation. While traditional, animal-derived vaccines are subject to ongoing advancements. Recombinant DNA technology has enabled the development of recombinant vaccines, reducing reliance on animal sources. These vaccines offer new possibilities for more precise and efficient immunization strategies. The continued exploration of innovative technologies in vaccine development is critical for improving safety, efficacy, and accessibility.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia